Suppr超能文献

基于霍恩和亚尔分期及病程的MDS-UPDRS评分差异

Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.

作者信息

Skorvanek Matej, Martinez-Martin Pablo, Kovacs Norbert, Rodriguez-Violante Mayela, Corvol Jean-Christophe, Taba Pille, Seppi Klaus, Levin Oleg, Schrag Anette, Foltynie Thomas, Alvarez-Sanchez Mario, Arakaki Tomoko, Aschermann Zsuzsanna, Aviles-Olmos Iciar, Benchetrit Eve, Benoit Charline, Bergareche-Yarza Alberto, Cervantes-Arriaga Amin, Chade Anabel, Cormier Florence, Datieva Veronika, Gallagher David A, Garretto Nelida, Gdovinova Zuzana, Gershanik Oscar, Grofik Milan, Han Vladimir, Huang Jing, Kadastik-Eerme Liis, Kurtis Monica M, Mangone Graziella, Martinez-Castrillo Juan Carlos, Mendoza-Rodriguez Amelia, Minar Michal, Moore Henry P, Muldmaa Mari, Mueller Christoph, Pinter Bernadette, Poewe Werner, Rallmann Karin, Reiter Eva, Rodriguez-Blazquez Carmen, Singer Carlos, Tilley Barbara C, Valkovic Peter, Goetz Christopher G, Stebbins Glenn T

机构信息

Department of Neurology P. J. Safarik University Kosice Slovak Republic.

Department of Neurology University Hospital L. Pasteur Kosice Slovak Republic.

出版信息

Mov Disord Clin Pract. 2017 Mar 11;4(4):536-544. doi: 10.1002/mdc3.12476. eCollection 2017 Jul-Aug.

Abstract

BACKGROUND

The Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a newly developed tool to assess Parkinson's disease (PD). Changes in scores on the scale over the course of PD, including increasing disease duration and Hoehn and Yahr (HY) stages, have not been described. The objectives of this study were to analyze MDS-UPDRS scores on Parts I through IV and their differences based on HY stage and disease duration in a large cohort of patients with PD.

METHODS

For this cross-sectional study, demographic data and MDS-UPDRS scores were collected, including HY stage. Subscores on MDS-UPDRS Parts I through IV were analyzed using 1-way analyses of variance for each HY stage and in 5-year increments of disease duration. Part III (motor assessment) scores were analyzed separately for on and off states.

RESULTS

The mean age of the 3206 patients was 65.8 ± 10.6 years, 53.3% were men, the mean disease duration was 11.5 ± 4.6 years, and the median HY stage was 2 (range, 0-5); 2156 patients were examined in an on state and 987 were examined in an off state. Scores for all MDS-UPDRS parts increased significantly through HY stages 1 through 5, with an average increase of 3.8, 7.7, 14.6, and 2.0 points consecutively for parts I through IV, respectively. For the 5-year increments of disease duration, MDS-UPDRS subscores increased by an average of 1.6, 3.3, 4.2, and 1.4 points consecutively for parts I through IV, respectively. This increase was significant only during the first 15 years of disease for all 4 parts, including part III scores evaluated in both on and off states.

CONCLUSIONS

MDS-UPDRS scores for all 4 parts increase significantly with every HY stage and also with 5-year increments of disease duration in the first 15 years of the disease.

摘要

背景

运动障碍学会统一帕金森病评定量表(MDS - UPDRS)是一种新开发的用于评估帕金森病(PD)的工具。该量表评分在PD病程中的变化,包括疾病持续时间增加以及霍恩和雅尔(HY)分期变化,尚未得到描述。本研究的目的是分析一大群PD患者中MDS - UPDRS第一至四部分的评分及其基于HY分期和疾病持续时间的差异。

方法

对于这项横断面研究,收集了人口统计学数据和MDS - UPDRS评分,包括HY分期。使用单因素方差分析对每个HY分期以及以5年为增量的疾病持续时间,分析MDS - UPDRS第一至四部分的子评分。第三部分(运动评估)评分分别针对开期和关期进行分析。

结果

3206例患者的平均年龄为65.8±10.6岁,男性占53.3%,平均疾病持续时间为11.5±4.6年,HY分期中位数为2(范围0 - 5);2156例患者在开期接受检查,987例患者在关期接受检查。所有MDS - UPDRS部分的评分在HY分期1至5期均显著增加,第一至四部分分别平均连续增加3.8、7.7、14.6和2.0分。对于以5年为增量的疾病持续时间,MDS - UPDRS子评分第一至四部分分别平均连续增加1.6、3.3、4.2和1.4分。这种增加仅在疾病的前15年对所有4个部分显著,包括在开期和关期评估的第三部分评分。

结论

在疾病的前15年,MDS - UPDRS所有4个部分的评分随每个HY分期以及5年的疾病持续时间增加而显著增加。

相似文献

1
Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration.
Mov Disord Clin Pract. 2017 Mar 11;4(4):536-544. doi: 10.1002/mdc3.12476. eCollection 2017 Jul-Aug.
2
Relationship between the MDS-UPDRS domains and the health-related quality of life of Parkinson's disease patients.
Eur J Neurol. 2014 Mar;21(3):519-24. doi: 10.1111/ene.12349. Epub 2014 Jan 21.
3
Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST.
Mov Disord Clin Pract. 2020 Apr 11;7(4):431-439. doi: 10.1002/mdc3.12939. eCollection 2020 May.
4
Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale.
Parkinsonism Relat Disord. 2015 Jan;21(1):50-4. doi: 10.1016/j.parkreldis.2014.10.026. Epub 2014 Nov 5.
6
Importance of focusing on subjective symptoms to maintain quality of life in patients with Parkinson's disease for over 5 years.
J Neurol Sci. 2024 Nov 15;466:123253. doi: 10.1016/j.jns.2024.123253. Epub 2024 Sep 29.
8
Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.
J Neurol Sci. 2015;353(1-2):87-91. doi: 10.1016/j.jns.2015.04.013. Epub 2015 Apr 17.

引用本文的文献

4
A composite measurement concept for monitoring cardiac function in Fabry disease.
Orphanet J Rare Dis. 2025 Jul 28;20(1):382. doi: 10.1186/s13023-025-03895-x.
6
10
The impact of sociodemographic factors and surgical modalities on deep brain stimulation for Parkinson's disease.
Surg Neurol Int. 2025 Mar 14;16:91. doi: 10.25259/SNI_968_2024. eCollection 2025.

本文引用的文献

1
Minimal clinically important difference on the Motor Examination part of MDS-UPDRS.
Parkinsonism Relat Disord. 2015 Dec;21(12):1421-6. doi: 10.1016/j.parkreldis.2015.10.006. Epub 2015 Oct 22.
3
The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system.
Parkinsonism Relat Disord. 2015 Mar;21(3):287-91. doi: 10.1016/j.parkreldis.2014.12.031. Epub 2015 Jan 5.
4
Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype.
Mov Disord. 2015 Mar;30(3):359-67. doi: 10.1002/mds.26110. Epub 2014 Dec 27.
5
Parkinson's disease severity levels and MDS-Unified Parkinson's Disease Rating Scale.
Parkinsonism Relat Disord. 2015 Jan;21(1):50-4. doi: 10.1016/j.parkreldis.2014.10.026. Epub 2014 Nov 5.
6
The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study).
Mov Disord. 2015 Feb;30(2):229-37. doi: 10.1002/mds.26077. Epub 2014 Dec 1.
7
Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
J Neurol. 2013 Jan;260(1):228-36. doi: 10.1007/s00415-012-6624-1. Epub 2012 Aug 5.
8
Relationships between disability, quality of life and prevalence of nonmotor symptoms in Parkinson's disease.
Parkinsonism Relat Disord. 2012 Jan;18(1):35-9. doi: 10.1016/j.parkreldis.2011.08.011. Epub 2011 Aug 31.
9
Systematic review of levodopa dose equivalency reporting in Parkinson's disease.
Mov Disord. 2010 Nov 15;25(15):2649-53. doi: 10.1002/mds.23429.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验